The adverse event profile of zonisamide: A meta-analysis

Acta Neurologica Scandinavica

Volumn 128, Issue 5, 2013, Pages 297-304

  Verrotti, A ^a   Loiacono, G ^a   Di Sabatino, F ^a   Zaccara, G ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Azienda Sanitaria di Firenze   (Italy)

Author keywords

Antiepileptic drug; Meta analysis; Safety; Systematic review; Zonisamide

Indexed keywords

CARBAMAZEPINE; PLACEBO; ZONISAMIDE;

ABDOMINAL PAIN; ABNORMAL THINKING; ADD ON THERAPY; ALCOHOLISM; ANOREXIA; ATAXIA; ATTENTION DISTURBANCE; BINGE EATING DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CARCINOMA; CAUSE OF DEATH; DECREASED APPETITE; DIZZINESS; DRUG INDUCED HEADACHE; EPILEPSY; ESSENTIAL TREMOR; FATIGUE; FOCAL EPILEPSY; HEART PALPITATION; HUMAN; INFANTILE SPASM; INSOMNIA; MANIA; MEMORY DISORDER; META ANALYSIS; MICTURITION DISORDER; MIGRAINE; MONOTHERAPY; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; PARANOIA; PARKINSON DISEASE; PHARYNGITIS; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; THORAX PAIN; THOUGHT DISORDER; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VARICOCELE; VOMITING; WEIGHT REDUCTION;

ANTIEPILEPTIC DRUG; META-ANALYSIS; SAFETY; SYSTEMATIC REVIEW; ZONISAMIDE;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; EPILEPSY; HUMANS; ISOXAZOLES;

EID: 84885419562     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12147     Document Type: Review

References (40)

1. Biton V. Zonisamide: newer antiepileptic agent with multiple mechanisms of action. Expert Rev Neurother 2004;4:935-43.
2. Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13(Suppl. 1):S5-9.
3. Jain KK. An assessment of zonisamide as an anti-epileptic drug. Expert Opin Pharmacother 2000;1:1245-60.
4. Seino M, Fujitani B. Clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS et al., eds. Antiepileptic drugs, 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2002.
5. Brodie MJ. Zonisamide clinical trials: European experience. Seizure 2004;13(Suppl. 1):S66-70.
6. Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46:31-41.
7. Faught E, Ayala R, Montouris GG, Leppik IE; Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774-9.
8. Lu Y, Xiao Z, Yu W et al. Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. Clin Drug Investig 2011;31:221-9.
9. Murata M, Hasegawa K, Kanazawa I; Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007;68:45-50.
10. McElroy SL, Kotwal R, Guerdjikova AI et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006;67:1897-906.
11. Sackellares JC, Ramsay RE, Wilder BJ, Browne TR, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45:610-7.
12. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003;327:557-60.
13. Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 2009;9:80+.
14. Anand A, Bukhari L, Jennings SA et al. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. J Clin Psychiatry 2005;66:195-8.
15. Bermejo PE, Dorado R. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol 2009;32:103-6.
16. Coppola G, Grosso S, Verrotti A et al. Zonisamide in children and young adults with refractory epilepsy: an open-label, multicenter Italian study. Epilepsy Res 2009;83:112-6.
17. Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin Neuropharmacol 2004;27:278-80.
18. Dupont S, Striano S, Trinka E et al. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS). Acta Neurol Scand 2010;121:141-8.
19. Eun SH, Kim HD, Eun BL et al. Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure 2011;20:558-63.
20. Ghaemi SN, Shirzadi AA, Klugman J, Berv DA, Pardo TB, Filkowsky MM. Is adjunctive open-label zonisamide effective for bipolar disorder? J Affect Disord 2008;105:311-4.
21. Ghaemi SN, Zablotsky B, Filkowski MM et al. An open-prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol 2006;26:385-8.
22. Griffith SG, Dai Y. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Clin Ther 2004;26:2056-65.
23. Heo K, Lee BI, Yi SD et al. Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: a multicenter open-label single-arm trial in Korean patients. Seizure 2012;21:188-93.
24. Kanba S, Yagi G, Kamijima K et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:707-15.
25. Kluger G, Zsoter A, Holthausen H. Long-term use of zonisamide in refractory childhood-onset epilepsy. Eur J Paediatr Neurol 2008;12:19-23.
26. Knapp CM, Sarid-Segal O, Richardson MA et al. Open label trial of the tolerability and efficacy of zonisamide in the treatment of alcohol dependence. Am J Drug Alcohol Abuse 2010;36:102-5.
27. Lee YJ, Kang HC, Seo JH, Lee JS, Kim HD. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. Brain Dev 2010;32:208-12.
28. Leppik IE, Willmore LJ, Homan RW et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993;14:165-73.
29. Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms. Neurology 2004;62:707-15.
30. Marinas A, Villanueva V, Giraldez BG, Molins A, Salas-Puig J, Serratosa JM. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord 2009;11:61-6.
31. Mc Elroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry 2004;65:50-6.
32. Mc Elroy SL, Suppes T, Keck PE Jr. et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry 2005;66:617-24.
33. Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. Seizure 2004;13(Suppl. 1):S17-23.
34. Newmark ME, Dubisky S. Zonisamide monotherapy in a multi-group clinic. Seizure 2004;13:223-5.
35. Ondo WG. Zonisamide for essential tremor. Clin Neuropharmacol 2007;30:345-9.
36. Rubio G, Lopez-Munoz F, Ferre F et al. Effect of zonisamide in the treatment of alcohol dependence. Clin Neuropharmacol 2010;33:250-3.
37. Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure 2004;13(Suppl. 1):S26-32.
38. Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol 2009;13:3-9.
39. Uthman BM, Miller GS, Montouris G, James SP, Anthony S. Safety of 25- and 50-mg capsules in the initiation of zonisamide therapy in patients with epilepsy: an uncontrolled, open-label study. Curr Med Res Opin 2004;20:837-4.
40. Vossler DG, Conry JA, Murphy JV. Zonisamide for the treatment of myoclonic epilepsy: an open label study. Epileptic Disord 2008;10:31-4.